Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease
Author:
Affiliation:
1. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
Publisher
Japan Academy
Subject
General Physics and Astronomy,General Agricultural and Biological Sciences,General Medicine
Link
https://www.jstage.jst.go.jp/article/pjab/93/8/93_PJA9308B-05/_pdf
Reference30 articles.
1. 1) Kuek, A., Hazleman, B.L. and Ostor, E.L. (2007) Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad. Med. J. 83, 251–260.
2. 2) Davidson, A. and Diamond, B. (2001) Autoimmune diseases. N. Engl. J. Med. 345, 340–350.
3. 3) Kopf, M., Bachmann, M.F. and Marsland, B.J. (2010) Averting inflammation by targeting the cytokine environment. Nat. Rev. Drug Discov. 9, 703–718.
4. 4) McInnes, I.B. and Schett, G. (2011) The pathogensis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205–2219.
5. 5) Smolen, J.S., Aletaha, D. and McInnes, I.B. (2016) Rheumatoid arthritis. Lancet 388, 2023–2038.
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Serum Concentrations of Infliximab and IL-6 for Predicting One-Year Discontinuation of Infliximab Treatment Owing to Secondary Non-response in Patients with Rheumatoid Arthritis;Biological and Pharmaceutical Bulletin;2023-08-01
2. Cytokines and cytokine receptors as targets of immune-mediated inflammatory diseases—RA as a role model;Inflammation and Regeneration;2022-12-01
3. Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B‐Lymphocyte Stimulating Factor Receptor‐Antibody Fusion Protein, in Healthy Chinese Subjects;Clinical Pharmacology in Drug Development;2022-07-17
4. ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial;Arthritis Research & Therapy;2020-10-21
5. Pursuit and New Trend in Rheumatoid Arthritis;Nihon Naika Gakkai Zasshi;2020-09-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3